Biogen Inc. (BIIB) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Drug Manufacturers - General industria. La empresa tiene su sede en Cambridge, MA, United States. El CEO actual es Christopher A. Viehbacher.
BIIB tiene fecha de IPO 1991-09-17, 7,605 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $26.26B.
Biogen Inc. is a global biopharmaceutical company founded in 1978 and headquartered in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for neurological and neurodegenerative diseases. The company maintains a robust portfolio of approved treatments across multiple therapeutic areas, including multiple sclerosis (TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, OCREVUS), spinal muscular atrophy (SPINRAZA), Alzheimer's disease (ADUHELM), and oncology and immunology indications (RITUXAN, GAZYVA), alongside a growing biosimilar franchise featuring etanercept, adalimumab, and infliximab biosimilars. Beyond its marketed products, Biogen maintains an extensive pipeline of investigational therapies targeting neurological disorders, including candidates for multiple sclerosis, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease, and immunology-related conditions. The company leverages strategic collaborations with leading pharmaceutical and biotechnology partners including Genentech, Eisai, Ionis Pharmaceuticals, and Sage Therapeutics to advance its research and development initiatives across its core therapeutic focus areas.
